US FDA Making BsUFA III Regulatory Science Grants Available Early
Executive Summary
Up to $1m per year per award is available for projects that address significant issues with biosimilar or interchangeable product development.
You may also be interested in...
Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.
Evidence And Education Must Support US Biosimilars
In the second part of an exclusive interview with Generics Bulletin, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, talks about the importance of real-world evidence and education in ensuring confidence in biosimilars, as well as the ongoing struggle against misinformation and the need for clarity over concepts such as interchangeability and unbranded biologics.
Remote Inspections: Stakeholders Seek Clarity As Some At US FDA Struggle With Process
Some lawmakers want FDA to prioritize in-person visits, but others are complaining that more remote inspections are needed because approvals are being delayed.